Baldwin et al. conducted a multicenter, prospective, randomized trial to compare the efficacy and hypoglycemic events of once-daily glargine plus three-times daily glulisine at 0.5 units/kg/day (high dose insulin group ) vs. 0.25 units/kg/day (low dose insulin group) in 107 T2DM subjects with glomerular filtration rate of <45 mL/min but who did not require dialysis [18]. The gene discussed is INS; the disease is type 2 diabetes mellitus.